← FDA DRUG APPROVALS

FDA ANDA · ANDA076166

CLONIDINE

Sponsor: MYLAN TECHNOLOGIES

APPLICATION
ANDA076166
TYPE
ANDA
ORIGINAL APPROVAL
2010-07-16
LATEST ACTION
2023-09-27
ROUTE
TRANSDERMAL
DOSAGE FORM
SYSTEM
MARKETING STATUS
Prescription

Products

CLONIDINEPrescription
CLONIDINE 0.2MG/24HR · SYSTEM · TRANSDERMAL
CLONIDINEPrescription
CLONIDINE 0.3MG/24HR · SYSTEM · TRANSDERMAL
CLONIDINEPrescription
CLONIDINE 0.1MG/24HR · SYSTEM · TRANSDERMAL

Approval history

2023-09-27Labeling · Supplement 19 · standardAP
2015-05-18Labeling · Supplement 5 · standardAP
2010-08-24Labeling · Supplement 2AP
2010-07-16OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →